Suzuken Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Suzuken Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Suzuken Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Suzuken Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Suzuken Co Ltd (Suzuken) is a distributor of pharmaceuticals, medical equipment and supplies, diagnostic reagents, and medical foods. The company's activities extend to the comprehensive development of medical and health-related businesses, including the research, development, and manufacturing of new drugs. The company has pipeline products that are useful for the treatment of type II diabetes, chronic kidney diseases and other dialysis-related areas with substantial unmet medical needs. It also provides support services for pharmaceutical manufacturers and operates pharmacy and nursing care businesses. Suzuken boasts a comprehensive distribution function, referred to as the healthcare distribution platform, which extends from pharmaceutical manufacturers to wholesalers, medical institutions, and pharmacies. Suzuken is headquartered in Nagoya, Aichi, Japan.
Headquarters
Japan
Address
8, Higashi Kataha-Machi, Higashi-Ku, Nagoya, Aichi, 461-8701
Website
www.suzuken.co.jp
Telephone
81 52 9612331
No of Employees
12,923
Industry
Wholesale
Ticker Symbol & Exchange
9987 (TYO)
Revenue (2025)
$16.0B
3.6%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
10.5%
(2025 vs 2024)
Market Cap*
$2.2B
Net Profit Margin (2025)
XYZ
6.3%
(2025 vs 2024)
* As of and is in US$
Suzuken Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pharmaceuticals | Pharmaceutical Distribution Services | UPASITA |
| Diagnostic Products | Contract Distribution Services | METOANA |
| Sphygmomanometers | Distribution of Orphan Drugs | LAGNOS |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In May, the company and Boksan Nice Co., Ltd entered into an agreement to acquire a 37% stake in Kyongnam Dongwon Pharmaceutical Wholesale Co., Ltd. |
| 2024 | Contracts/Agreements | In May, the company along with Sanwa Kagaku Kenkyusho Co. and Bushu Pharmaceuticals Ltd entered into a partnership agreement with EPS Holdings for a joint business to help the launch of drug loss products in Japan. |
| 2024 | Plans/Strategy | In March, the company announced its plans to begin operations at the Greater Tokyo Distribution Center in Soka, Saitama Prefecture, Japan. |
Competitor Comparison
| Key Parameters | Suzuken Co Ltd | Alfresa Holdings Corp | Sumitomo Chemical Co Ltd | Astellas Pharma Inc | Kyowa Kirin Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Nagoya | Chiyoda-Ku | Chuo-Ku | Chuo-Ku | Chiyoda-Ku |
| State/Province | Aichi | Tokyo | Tokyo | Tokyo | Tokyo |
| No. of Employees | 12,923 | 12,452 | 29,279 | 13,643 | 5,161 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Hiromi Miyata | Chairman | Executive Board | 2024 | 66 |
| Shigeru Asano | Director; President; Chief Executive Officer | Executive Board | 2022 | 60 |
| Chie Takahashi | ; Senior Executive Officer; Senior General Manager - Healthcare Solutions Business; Director; Senior General Manager - Solutions Business Planning Dept. | Executive Board | 2024 | 59 |
| Kenji Nameda | Executive Officer | Senior Management | - | - |
| Koji Momobayashi | Executive Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer